BIOTECH Logo

BIOTECH

A biotechnology group offering preclinical services, intein development, and licensing.

BST | BME Growth

Overview

Corporate Details

ISIN(s):
ES0184980003 (+1 more)
LEI:
959800GNYT6ZZEWPEW29
Country:
Spain
Address:
AVDA. DEL DESARROLLO TECNOLOGICO (PARQUE CIENTIFICO TECNOLOGICO AGROINDUSTRIAL) 11, 11591 Jerez de la Frontera

Description

Biotechnology Assets Biat Group is a biotechnology corporate group with a global commercial structure operating through several subsidiaries. Its subsidiary Biobide is a provider of preclinical services, specializing in tailor-made toxicity and efficacy testing using the zebrafish (ZF) animal model. ZIP Solutions develops and promotes a proprietary set of inteins for high-value industrial applications, including gene therapy, immunotherapy, in-vitro diagnostics, smart vaccines (RNA & DNA), and affinity-based protein purification. The Bionatur division manages biotech assets for human and animal health. The group focuses on licensing its platforms and products, conducting preclinical research, and improving recombinant and DNA vaccines through collaborations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-19 14:18
Net Asset Value(s)
English 4.0 KB
2025-03-18 10:30
Net Asset Value(s)
English 4.0 KB
2025-03-17 14:38
Net Asset Value(s)
English 4.0 KB
2025-03-14 10:53
Net Asset Value(s)
English 4.0 KB
2025-03-13 15:33
Net Asset Value(s)
English 4.0 KB
2025-03-12 14:50
Net Asset Value(s)
English 4.1 KB
2025-03-11 15:54
Net Asset Value(s)
English 4.0 KB
2025-03-10 14:35
Net Asset Value(s)
English 4.0 KB
2025-03-07 14:28
Net Asset Value(s)
English 4.0 KB
2025-03-07 09:08
Net Asset Value(s)
English 4.0 KB
2025-03-06 15:30
Net Asset Value(s)
English 4.0 KB
2025-03-06 08:00
Net Asset Value(s)
English 4.0 KB
2025-03-05 14:34
Net Asset Value(s)
English 4.0 KB
2025-03-04 14:40
Net Asset Value(s)
English 4.0 KB
2025-03-03 15:43
Net Asset Value(s)
English 4.0 KB

Automate Your Workflow. Get a real-time feed of all BIOTECH filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOTECH

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOTECH via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nicox S.A. Logo
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
France
COX
NLS Pharmaceutics Ltd. Logo
Clinical-stage biopharma firm developing therapies for rare and complex CNS disorders.
United States of America
NLSP
NovoCure Ltd Logo
Develops a non-invasive cancer therapy using electric fields to disrupt solid tumors.
United States of America
NVCR
NUFORMIX PLC Logo
Pharmaceutical developer using cocrystal technology to repurpose drugs for fibrosis.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Clinical-stage biopharma developing protein degradation therapies for various diseases.
United States of America
NRIX
OLIPASS CORPORATION Logo
An R&D company developing RNA therapeutics using its proprietary OPNA platform.
South Korea
244460
A technology platform for therapeutic antibody discovery using transgenic animals.
United States of America
OABIW
ONCIMMUNE HOLDINGS PLC Logo
Immunodiagnostics company specializing in antibody and autoantibody biomarker signatures.
United Kingdom
ONC
Oncocross Co.,Ltd. Logo
An AI biotechnology firm that develops drugs by predicting drug-disease interactions.
South Korea
382150
ONCODESIGN Logo
Develops therapeutic and diagnostic solutions for resistant and metastatic cancers.
France
ALONC

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.